Clinical evaluation examines delayed immunotherapy initiation in stage IV non-small cell lung cancer, highlighting the prognostic role of treatment timing.
Currently, the established approach for addressing stage IV non-small cell lung cancer (NSCLC) involves combining chemotherapy with immunotherapy. However, the necessity for molecular analysis prior to commencing immunotherapy often results in a delay in its initiation following the commencement of chemotherapy. Therefore, this study aimed to study the significance of postponing immunotherapy on pertinent patient outcomes.
No takes yet. Share an insight, caveat, or question.
Vázquez-Urrutia et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: